QNCX Insider Trading Activity and SEC Form 4 Filings
QNCX insider trading summary
No open-market insider purchases or sales of Quince Therapeutics, Inc. (QNCX) have been reported on SEC Form 4 in the past 12 months.
Latest QNCX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 30, 2024 | Dirk Thye | CEO and Chief Medical Officer | Buy | $54K (77,000 @ $0.70) |
| Aug 29, 2024 | Dirk Thye | CEO and Chief Medical Officer | Buy | $53K (77,500 @ $0.69) |
| Aug 21, 2024 | Brendan Hannah | Chief Business Officer and COO | Buy | $1K (2,280 @ $0.61) |
| Aug 21, 2024 | Brendan Hannah | Chief Business Officer and COO | Buy | $15K (23,565 @ $0.63) |
| Aug 21, 2024 | Brendan Hannah | Chief Business Officer and COO | Buy | $3K (5,000 @ $0.62) |
| Aug 20, 2024 | Brendan Hannah | Chief Business Officer and COO | Buy | $2K (3,424 @ $0.60) |
| Aug 20, 2024 | Charles S. Ryan | President | Buy | $31K (48,387 @ $0.65) |
| Aug 20, 2024 | Brendan Hannah | Chief Business Officer and COO | Buy | $2K (2,500 @ $0.61) |
| Aug 19, 2024 | Brendan Hannah | Chief Business Officer and COO | Buy | $1K (2,155 @ $0.58) |
| Dec 14, 2023 | David Lamond | Director | Buy | $24K (22,627 @ $1.04) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.